{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:37:58Z","timestamp":1761975478378,"version":"3.40.5"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,2,15]],"date-time":"2015-02-15T00:00:00Z","timestamp":1423958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00018-015-1854-x","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T09:27:43Z","timestamp":1424165263000},"page":"2107-2117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Molecular imaging of levodopa-induced dyskinesias"],"prefix":"10.1007","volume":"72","author":[{"given":"Flavia","family":"Niccolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"1854_CR1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/123.4.665","volume":"123","author":"BK MacDonald","year":"2000","unstructured":"MacDonald BK, Cockerell OC, Sander WAS, Shorvon SD (2000) The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123:665\u2013676","journal-title":"Brain"},{"key":"1854_CR2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesisa and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448\u2013458","journal-title":"Mov Disord"},{"key":"1854_CR3","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol 2:382\u2013392","journal-title":"Nat Clin Pract Neurol"},{"key":"1854_CR4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3181d90050","volume":"74","author":"JG Nutt","year":"2010","unstructured":"Nutt JG, Chung KA, Holford NH (2010) Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 74:1191\u20131197","journal-title":"Neurology"},{"issue":"Suppl 11","key":"1854_CR5","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","volume":"20","author":"J Jankovic","year":"2005","unstructured":"Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson\u2019s disease: clinical manifestations. Mov Disord 20(Suppl 11):S11\u2013S16","journal-title":"Mov Disord"},{"key":"1854_CR6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22:1379\u20131389","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"1854_CR7","first-page":"S56","volume":"64","author":"S Fahn","year":"2008","unstructured":"Fahn S (2008) How do you treat motor complications in Parkinson\u2019s disease: medicine, surgery, or both? Ann Neurol 64(Suppl 2):S56\u2013S64","journal-title":"Ann Neurol"},{"key":"1854_CR8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00702-012-0796-9","volume":"119","author":"A Khlebtovsky","year":"2012","unstructured":"Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R (2012) Patient and caregiver perceptions of the social impact of advanced Parkinson\u2019s disease and dyskinesias. J Neural Transm 119:1367\u20131371","journal-title":"J Neural Transm"},{"issue":"1\u20132","key":"1854_CR9","first-page":"24","volume":"319","author":"DC Suh","year":"2012","unstructured":"Suh DC, Pahwa R, Mallya U (2012) Treatment patterns and associated costs with Parkinson\u2019s disease levodopa induced dyskinesia. J Neurol Sci 319(1\u20132):24\u201331","journal-title":"J Neurol Sci"},{"key":"1854_CR10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","volume":"9","author":"P Calabresi","year":"2010","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson\u2019s disease: filling the bench-to-bedside gap. Lancet Neurol 9:1106\u20131117","journal-title":"Lancet Neurol"},{"key":"1854_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2006.01.009","volume":"22","author":"W Meissner","year":"2006","unstructured":"Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22:586\u2013598","journal-title":"Neurobiol Dis"},{"key":"1854_CR12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1471-4159.2009.06556.x","volume":"112","author":"HS Lindgren","year":"2010","unstructured":"Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) L DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson\u2019s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112:1456\u20131476","journal-title":"J Neurochem"},{"key":"1854_CR13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/230331a0","volume":"230","author":"KY Ng","year":"1971","unstructured":"Ng KY, Colburn RW, Kopin IJ (1971) Effects of l-dopa on efflux of cerebral monoamines from synaptosomes. Nature 230:331\u2013332","journal-title":"Nature"},{"key":"1854_CR14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","volume":"195","author":"R Arai","year":"1995","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu I (1995) l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a doublelabeling immunofluorescence study. Neurosci Lett 195:195\u2013198","journal-title":"Neurosci Lett"},{"key":"1854_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-8993(94)91511-3","volume":"667","author":"R Arai","year":"1994","unstructured":"Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res 667:295\u2013299","journal-title":"Brain Res"},{"key":"1854_CR16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","volume":"10","author":"H Tanaka","year":"1999","unstructured":"Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in l-DOPA derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10:631\u2013634","journal-title":"NeuroReport"},{"key":"1854_CR17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brainres.2005.04.019","volume":"1046","author":"T Maeda","year":"2005","unstructured":"Maeda T, Nagata K, Yoshida Y, Kannari K (2005) Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 1046:230\u2013233","journal-title":"Brain Res"},{"key":"1854_CR18","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"key":"1854_CR19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:18\u201329","journal-title":"Neurology"},{"key":"1854_CR20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","volume":"87","author":"KL Eskow","year":"2007","unstructured":"Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improvesl-DOPA efficacy. Pharmacol Biochem Behav 87:306\u2013314","journal-title":"Pharmacol Biochem Behav"},{"key":"1854_CR21","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","volume":"131","author":"A Mu\u00f1oz","year":"2008","unstructured":"Mu\u00f1oz A, Qin L, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Bj\u00f6rklund A, Bezard E, Carta M (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 131:3380\u20133394","journal-title":"Brain"},{"key":"1854_CR22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","volume":"219","author":"A Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz A, Carlsson T, Tronci E, Kirik, Bj\u00f6rklund A, Carta M (2009) Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exper Neurol 219:298\u2013307","journal-title":"Exper Neurol"},{"key":"1854_CR23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","volume":"87","author":"C Bishop","year":"2009","unstructured":"Bishop C, Krolewski D, Eskow K, Barnum C, Dupre K, Deak T, Walker P (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in l-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87:1645\u20131658","journal-title":"J Neurosci Res"},{"key":"1854_CR24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","volume":"15","author":"L Gr\u00e9goire","year":"2009","unstructured":"Gr\u00e9goire L, Samadi P, Grahama J, Bedard P, Bartoszyk G, Di Paolo T (2009) Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys. Parkins Rel Disord 15:445\u2013452","journal-title":"Parkins Rel Disord"},{"key":"1854_CR25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"1461","author":"C Loane","year":"2012","unstructured":"Loane C, Politis M (2012) Buspirone: what is it all about? Brain Res 1461:111\u2013118","journal-title":"Brain Res"},{"issue":"4","key":"1854_CR26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neures.2013.10.002","volume":"77","author":"E B\u00e9zard","year":"2013","unstructured":"B\u00e9zard E, Mu\u00f1oz A, Tronci E, Pioli EY, Li Q, Porras G, Bj\u00f6rklund A, Carta M (2013) Anti-dyskinetic effect of anpirtoline in animal models of l-DOPA-induced dyskinesia. Neurosci Res 77(4):242\u2013246","journal-title":"Neurosci Res"},{"key":"1854_CR27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001756-200505120-00009","volume":"16","author":"LJ Mignon","year":"2005","unstructured":"Mignon LJ, Wolf WA (2005) 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson\u2019s disease. NeuroReport 16:699\u2013703","journal-title":"NeuroReport"},{"key":"1854_CR28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","volume":"55","author":"KB Dupre","year":"2008","unstructured":"Dupre KB, Eskow KL, Barnum CJ, Bishop C (2008) Striatal 5-HT(1A) receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55:1321\u20131328","journal-title":"Neuropharmacology"},{"issue":"2","key":"1854_CR29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.brainresbull.2010.12.006","volume":"84","author":"SJ Gil","year":"2011","unstructured":"Gil SJ, Park CH, Lee JE, Minn YK, Koh HC (2011) Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats. Brain Res Bull 84(2):151\u2013156","journal-title":"Brain Res Bull"},{"key":"1854_CR30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","volume":"6","author":"PJ Conn","year":"2005","unstructured":"Conn PJ, Battaglia G, Marino MJ, Nicoletti F (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6:787\u2013798","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"1854_CR31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00702-014-1176-4","volume":"121","author":"C Finlay","year":"2014","unstructured":"Finlay C, Duty S (2014) Therapeutic potential of targeting glutamate receptors in Parkinson\u2019s disease. J Neural Transm 121(8):861\u2013880","journal-title":"J Neural Transm"},{"issue":"1","key":"1854_CR32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389","journal-title":"Behav Brain Res"},{"key":"1854_CR33","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/brain\/awf269","volume":"125","author":"B Picconi","year":"2002","unstructured":"Picconi B, Pisani A, Centonze D, Battaglia G, Storto M, Nicoletti F, Bernardi G, Calabresi P (2002) Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. Brain 125:2635\u20132645","journal-title":"Brain"},{"key":"1854_CR34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.neuropharm.2007.08.009","volume":"54","author":"P Samadi","year":"2008","unstructured":"Samadi P, Gr\u00e9goire L, Morissette M, Calon F, Hadj Tahar A, B\u00e9langer N, Dridi M, B\u00e9dard PJ, Di Paolo T (2008) Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of l-Dopa-induced dyskinesias. Neuropharmacology 54:258\u2013268","journal-title":"Neuropharmacology"},{"issue":"1","key":"1854_CR35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","volume":"330","author":"D Rylander","year":"2009","unstructured":"Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330(1):227\u2013235","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR36","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","volume":"29","author":"P Samadi","year":"2008","unstructured":"Samadi P, Gr\u00e9goire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, B\u00e9dard PJ, Di Paolo T (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 29:1040\u20131051","journal-title":"Neurobiol Aging"},{"key":"1854_CR37","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","volume":"32","author":"B Ouattara","year":"2011","unstructured":"Ouattara B, Gr\u00e9goire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T (2011) Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 32:1286\u20131295","journal-title":"Neurobiol Aging"},{"key":"1854_CR38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","volume":"69","author":"A Dekundy","year":"2006","unstructured":"Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson\u2019s disease. Brain Res Bull 69:318\u2013326","journal-title":"Brain Res Bull"},{"key":"1854_CR39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","volume":"101","author":"F Mela","year":"2007","unstructured":"Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson\u2019s disease. J Neurochem 101:483\u2013497","journal-title":"J Neurochem"},{"key":"1854_CR40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","volume":"39","author":"D Rylander","year":"2010","unstructured":"Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA (2010) A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 39:352\u2013361","journal-title":"Neurobiol Dis"},{"key":"1854_CR41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00702-010-0526-0","volume":"118","author":"A Dekundy","year":"2011","unstructured":"Dekundy A, Gravius A, Hechenberger M, Pietraszek M, Nagel J, Tober C, van der Elst M, Mela F, Parsons CG, Danysz W (2011) Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. J Neural Transm 118:1703\u20131716","journal-title":"J Neural Transm"},{"key":"1854_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","volume":"17","author":"L Gr\u00e9goire","year":"2011","unstructured":"Gr\u00e9goire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 17:270\u2013276","journal-title":"Parkinsonism Relat Disord"},{"key":"1854_CR43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/978-3-540-89615-9_18","volume":"193","author":"M Morelli","year":"2009","unstructured":"Morelli M, Carta AR, Jenner P (2009) Adenosine A2A receptors and Parkinson\u2019s disease. Handb Exp Pharmacol 193:589\u2013615","journal-title":"Handb Exp Pharmacol"},{"key":"1854_CR44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","volume":"127","author":"F Calon","year":"2004","unstructured":"Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias. Brain 127:1075\u20131084","journal-title":"Brain"},{"key":"1854_CR45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/syn.20295","volume":"60","author":"M Morissette","year":"2006","unstructured":"Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, B\u00e9dard PJ, Di Paolo T (2006) Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse 60:239\u2013250","journal-title":"Synapse"},{"key":"1854_CR46","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1046\/j.1460-9568.2000.00988.x","volume":"12","author":"BY Zeng","year":"2000","unstructured":"Zeng BY, Pearce RK, MacKenzie GM, Jenner P (2000) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA. Eur J Neurosci 12:1096\u20131104","journal-title":"Eur J Neurosci"},{"key":"1854_CR47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","volume":"184","author":"F Bibbiani","year":"2003","unstructured":"Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN (2003) A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson\u2019s disease. Exp Neurol 184:285\u2013294","journal-title":"Exp Neurol"},{"key":"1854_CR48","doi-asserted-by":"crossref","first-page":"9226","DOI":"10.1073\/pnas.97.16.9226","volume":"97","author":"ME Phelps","year":"2000","unstructured":"Phelps ME (2000) Positron emission tomography provides molecular imaging of biological processes. PNAS 97:9226\u20139233","journal-title":"PNAS"},{"issue":"4","key":"1854_CR49","first-page":"323","volume":"3","author":"C Loane","year":"2011","unstructured":"Loane C, Politis M (2011) Positron emission tomography neuroimaging in Parkinson\u2019s disease. Am J Transl Res. 3(4):323\u2013341","journal-title":"Am J Transl Res."},{"key":"1854_CR50","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00415-012-6428-3","volume":"259","author":"M Politis","year":"2012","unstructured":"Politis M, Piccini P (2012) Positron emission tomography imaging in neurological disorders. J Neurol 259:1769\u20131780","journal-title":"J Neurol"},{"key":"1854_CR51","doi-asserted-by":"crossref","unstructured":"Politis M, Niccolini F (2015) Serotonin in Parkinson\u2019s disease. Behav Brain Res 277:136\u2013145","DOI":"10.1016\/j.bbr.2014.07.037"},{"key":"1854_CR52","doi-asserted-by":"crossref","unstructured":"Niccolini F, Su P, Politis M (2014) Dopamine receptor mapping with PET imaging in Parkinson\u2019s disease. J Neurol 261:2251\u20132263","DOI":"10.1007\/s00415-014-7302-2"},{"issue":"694\u20139","key":"1854_CR53","first-page":"e39","volume":"21","author":"F Niccolini","year":"2014","unstructured":"Niccolini F, Loane C, Politis M (2014) Dyskinesias in Parkinson\u2019s disease: views from positron emission tomography studies. Eur J Neurol 21(694\u20139):e39\u2013e43","journal-title":"Eur J Neurol"},{"key":"1854_CR54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","volume":"49","author":"R Fuente-Fernandez de la","year":"2001","unstructured":"de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ (2001) Biochemical variations in the synaptic levels of dopamine precede motor fluctuations in Parkinson\u2019s disease: PET evidence of increased dopamine turnover. Ann Neurol 49:298\u2013303","journal-title":"Ann Neurol"},{"key":"1854_CR55","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00004647-200110000-00003","volume":"21","author":"R Fuente-Fern\u00e1ndez de la","year":"2001","unstructured":"de la Fuente-Fern\u00e1ndez R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ (2001) Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 21:1151\u20131159","journal-title":"J Cereb Blood Flow Metab"},{"key":"1854_CR56","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","volume":"127","author":"R Fuente-Fernandez de la","year":"2004","unstructured":"de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu QR, Calne DB, Ruth TJ, Stoessl AJ (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias. Brain 127:2747\u20132754","journal-title":"Brain"},{"key":"1854_CR57","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","volume":"67","author":"N Pavese","year":"2006","unstructured":"Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P (2006) Clinical correlates of levodopa induced dopamine release in Parkinson\u2019s disease: a PET study. Neurology 67:1612\u20131617","journal-title":"Neurology"},{"key":"1854_CR58","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis M, Wu K, Loane C, Brooks DJ, Kiferle L, Turkheimer FE, Bain P, Molloy S, Piccini P (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Invest 124:1340\u20131349","journal-title":"J Clin Invest"},{"key":"1854_CR59","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Laska E, Hicking C, Damier P, M\u00fcller T, Nutt J, Warren Olanow C, Rascol O, Russ H (2008) Placebo influences on dyskinesia in Parkinson\u2019s disease. Mov Disord 23:700\u2013707","journal-title":"Mov Disord"},{"issue":"Suppl 15","key":"1854_CR60","first-page":"S591","volume":"21","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Olanow CW, Nutt J (2006) The PADDY-2 study: the evaluation of sarizotan for treatment-associated dyskinesia in Parkinson\u2019s disease patients. Mov Disord 21(Suppl 15):S591","journal-title":"Mov Disord"},{"key":"1854_CR61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, M\u00fcller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22:179\u2013186","journal-title":"Mov Disord"},{"key":"1854_CR62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P Hagell","year":"2002","unstructured":"Hagell P, Piccini P, Bj\u00f6rklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O (2002) Dyskinesias following neural transplantation in Parkinson\u2019s disease. Nat Neurosci 5:627\u2013628","journal-title":"Nat Neurosci"},{"key":"1854_CR63","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.10359","volume":"52","author":"Y Ma","year":"2002","unstructured":"Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D (2002) Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52:628\u2013634","journal-title":"Ann Neurol"},{"key":"1854_CR64","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.22208","volume":"24","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Gracies JM, Goetz CG, Stoessl AJ, Freeman T, Kordower JH, Godbold J, Obeso JA (2009) Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson\u2019s disease: a double blind video-based analysis. Mov Disord 24:336\u2013343","journal-title":"Mov Disord"},{"key":"1854_CR65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P (2010) Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci Transl Med 2:38\u201346","journal-title":"Sci Transl Med"},{"key":"1854_CR66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-8-80","volume":"8","author":"M Politis","year":"2010","unstructured":"Politis M (2010) Dyskinesias after neural transplantation in Parkinson\u2019s disease: what do we know and what is next? BMC Med 8:80","journal-title":"BMC Med"},{"key":"1854_CR67","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","volume":"26","author":"M Politis","year":"2011","unstructured":"Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P (2011) Graft-induced dyskinesias in Parkinson\u2019s disease: high striatal serotonin\/dopamine transporter ratio. Mov Disord 26:1997\u20132003","journal-title":"Mov Disord"},{"key":"1854_CR68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1126\/scitranslmed.3003391","volume":"4","author":"M Politis","year":"2012","unstructured":"Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Oertel WH, Bj\u00f6rklund A, Lindvall O, Piccini P (2012) Serotonin neuron loss and nonmotor symptoms continue in Parkinson\u2019s patients treated with dopamine grafts. Sci Transl Med 4:128\u2013141","journal-title":"Sci Transl Med"},{"key":"1854_CR69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0079-6123(10)84010-5","volume":"184","author":"M Politis","year":"2010","unstructured":"Politis M, Piccini P (2010) Brain imaging after neural transplantation. Prog Brain Res 184:193\u2013203","journal-title":"Prog Brain Res"},{"key":"1854_CR70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-444-59575-1.00009-0","volume":"2000","author":"M Politis","year":"2012","unstructured":"Politis M, Piccini P (2012) In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res 2000:199\u2013220","journal-title":"Prog Brain Res"},{"key":"1854_CR71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jamaneurol.2013.4749","volume":"71","author":"Z Kefalopoulou","year":"2014","unstructured":"Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Bj\u00f6rklund A, Lindvall O, Limousin P, Quinn N, Foltynie T (2014) Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 71:83\u201387","journal-title":"JAMA Neurol"},{"issue":"1461","key":"1854_CR72","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","volume":"21","author":"C Loane","year":"2012","unstructured":"Loane C, Politis M (2012) Buspirone: what is it all about? Brain Res 21(1461):111\u2013118","journal-title":"Brain Res"},{"key":"1854_CR73","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","volume":"26","author":"S Duty","year":"2012","unstructured":"Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson\u2019s disease. CNS Drugs 26:1017\u20131032","journal-title":"CNS Drugs"},{"key":"1854_CR74","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/brain\/awr028","volume":"134","author":"I Ahmed","year":"2011","unstructured":"Ahmed I, Bose S, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ (2011) Glutamate NMDA receptor dysregulation in Parkinson\u2019s disease with dyskinesias. Brain 134:979\u2013986","journal-title":"Brain"},{"key":"1854_CR75","first-page":"CD003467","volume":"2","author":"NJ Crosby","year":"2003","unstructured":"Crosby NJ, Deane K, Clarke CE (2003) Amantadine for dyskinesia in Parkinson\u2019s disease. Cochrane Database Syst Rev 2:CD003467","journal-title":"Cochrane Database Syst Rev"},{"key":"1854_CR76","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50:1323\u20131326","journal-title":"Neurology"},{"key":"1854_CR77","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger E, Wenning GK, B\u00f6sch S, Poewe W (2000) Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15:873\u2013878","journal-title":"Mov Disord"},{"key":"1854_CR78","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","volume":"23","author":"BJ Snow","year":"2000","unstructured":"Snow BJ, Macdonald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23:82\u201385","journal-title":"Clin Neuropharmacol"},{"key":"1854_CR79","first-page":"141","volume":"75","author":"A Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatr 75:141\u2013143","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"1854_CR80","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","volume":"26","author":"D Berg","year":"2011","unstructured":"Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243\u20131250","journal-title":"Mov Disord"},{"key":"1854_CR81","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","volume":"28","author":"F Stocchi","year":"2013","unstructured":"Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C (2013) AFQ056 in Parkinson patients with l-DOPA-induced dyskinesia: 13-week dose-finding study. Mov Disord 28:1838\u20131846","journal-title":"Mov Disord"},{"key":"1854_CR82","doi-asserted-by":"crossref","first-page":"e17338","DOI":"10.1371\/journal.pone.0017338","volume":"6","author":"M Mishina","year":"2011","unstructured":"Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K (2011) Adenosine A2A receptors measured with [11C]TMSX PET in the striata of Parkinson\u2019s disease patients. PLoS One 6:e17338","journal-title":"PLoS One"},{"key":"1854_CR83","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.0b013e31821ccce4","volume":"76","author":"AF Ramlackhansingh","year":"2011","unstructured":"Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ (2011) Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76:1811\u20131816","journal-title":"Neurology"},{"key":"1854_CR84","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, Japanese Istradefylline Study Group (2010) Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study. Mov Disord 25:1437\u20131443","journal-title":"Mov Disord"},{"key":"1854_CR85","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","volume":"18","author":"E Pourcher","year":"2012","unstructured":"Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P (2012) Istradefylline for Parkinson\u2019s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 18:178\u2013184","journal-title":"Parkinsonism Relat Disord"},{"key":"1854_CR86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","volume":"10","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221\u2013229","journal-title":"Lancet Neurol"},{"key":"1854_CR87","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2006.08.002","volume":"27","author":"P Samadi","year":"2006","unstructured":"Samadi P, Bedard PJ, Rouillard C (2006) Opioids and motor complications in Parkinson\u2019s disease. Trends Pharmacol Sci 27:512\u2013517","journal-title":"Trends Pharmacol Sci"},{"key":"1854_CR88","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.410420508","volume":"42","author":"P Piccini","year":"1997","unstructured":"Piccini P, Ra Weeks, Brooks DJ (1997) Alterations in opioid receptor binding in Parkinson\u2019s disease patients with levodopa-induced dyskinesias. Ann Neurol 42:720\u2013726","journal-title":"Ann Neurol"},{"key":"1854_CR89","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/jcbfm.1992.122","volume":"12","author":"B Sadzot","year":"1992","unstructured":"Sadzot B, Price JC, Mayberg HS, Douglass KH, Dannals RF, Lever JR, Ravert HT, Wilson AA, Wagner HN Jr, Feldman MA (1992) Quantification of human opiate receptor concentration and affinity using high and low specific activity [11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 12:885","journal-title":"J Cereb Blood Flow Metab"},{"key":"1854_CR90","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in the rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563\u2013583","journal-title":"J Neurosci"},{"key":"1854_CR91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(92)90832-R","volume":"148","author":"P Mailleux","year":"1992","unstructured":"Mailleux P, Vanderhaeghen JJ (1992) Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 148:173\u2013176","journal-title":"Neurosci Lett"},{"key":"1854_CR92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","volume":"77","author":"M Glass","year":"1997","unstructured":"Glass M, Dragunow M, Faull RLM (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299\u2013318","journal-title":"Neuroscience"},{"key":"1854_CR93","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.npp.1301558","volume":"33","author":"AB Mart\u00edn","year":"2008","unstructured":"Mart\u00edn AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M, de Fonseca FR, Moratalla R (2008) Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 33:1667\u20131679","journal-title":"Neuropsychopharmacology"},{"key":"1854_CR94","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.neurobiolaging.2011.02.009","volume":"33","author":"K Laere van","year":"2012","unstructured":"van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, Vandenberghe W (2012) Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo. Neurobiol Aging 33:620","journal-title":"Neurobiol Aging"},{"key":"1854_CR95","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"KA Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111","journal-title":"Neurology"},{"key":"1854_CR96","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/mds.20111","volume":"19","author":"K Venderov\u00e1","year":"2004","unstructured":"Venderov\u00e1 K, R\u016fzicka E, Vor\u00edsek V, Visnovsk\u00fd P (2004) Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 19:1102\u20131106","journal-title":"Mov Disord"},{"key":"1854_CR97","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/neu.10150","volume":"53","author":"FM Zhou","year":"2002","unstructured":"Zhou FM, Wilson CJ, Dani JA (2002) Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 53:590\u2013605","journal-title":"J Neurobiol"},{"key":"1854_CR98","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1073\/pnas.1032899100","volume":"100","author":"Y Kitabatake","year":"2003","unstructured":"Kitabatake Y, Hikida T, Watanabe D, Pastan I, Nakanishi S (2003) Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc Natl Acad Sci USA 100:7965\u20137970","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1854_CR99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuron.2014.01.023","volume":"82","author":"AB Nelson","year":"2014","unstructured":"Nelson AB, Hammack N, Yang CF, Shah NM, Seal RP, Kreitzer AC (2014) Striatal cholinergic interneurons Drive GABA release from dopamine terminals. Neuron 82(1):63\u201370","journal-title":"Neuron"},{"key":"1854_CR100","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","volume":"62","author":"M Quik","year":"2007","unstructured":"Quik M, Cox H, Parameswaran N, O\u2019Leary K, Langston JW, Di Monte D (2007) Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588\u2013596","journal-title":"Ann Neurol"},{"key":"1854_CR101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","volume":"327","author":"T Bordia","year":"2008","unstructured":"Bordia T, Campos C, Huang L, Quik M (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson\u2019s disease. J Pharmacol Exp Ther 327:239\u2013247","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR102","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","volume":"338","author":"L Huang","year":"2011","unstructured":"Huang L, Grady SR, Quik M (2011) Nicotine reduces l-DOPA-induced dyskinesias by acting at beta2 nicotinic receptors. J Pharmacol Exp Ther 338:932\u2013941","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR103","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","volume":"28","author":"M Quik","year":"2013","unstructured":"Quik M, Mallela A, Ly J, Zhang D (2013) Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson\u2019s disease. Mov Disord 28:1398\u20131406","journal-title":"Mov Disord"},{"key":"1854_CR104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","volume":"347","author":"D Zhang","year":"2013","unstructured":"Zhang D, Mallela A, Sohn D, Carroll FI, Bencherif M, Letchworth S, Quik M (2013) Nicotinic receptor agonists reduce l-DOPA-induced dyskinesias in a monkey model of Parkinson\u2019s disease. J Pharmacol Exp Ther 347:225\u2013234","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(91)90588-M","volume":"547","author":"JO Rinne","year":"1991","unstructured":"Rinne JO, Myllykyla T, Lonnberg P, Marjamaki P (1991) A postmortem study of brain nicotinic receptors in Parkinson\u2019s and Alzheimer\u2019s disease. Brain Res 547:167\u2013170","journal-title":"Brain Res"},{"key":"1854_CR106","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1471-4159.2004.02177.x","volume":"88","author":"M Quik","year":"2004","unstructured":"Quik M, Bordia T, Forno L, McIntosh JM (2004) Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson\u2019s disease striatum. J Neurochem 88:668\u2013679","journal-title":"J Neurochem"},{"key":"1854_CR107","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nucmedbio.2005.12.012","volume":"33","author":"J Schmaljohann","year":"2006","unstructured":"Schmaljohann J, Gundisch D, Minnerop M, Bucerius J, Joe A, Reinhardt M, Guhlke S, Biersack HJ, Wullner U (2006) In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson\u2019s disease. Nucl Med Biol 33:305\u2013309","journal-title":"Nucl Med Biol"},{"key":"1854_CR108","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/jcbfm.2009.74","volume":"29","author":"A Kas","year":"2009","unstructured":"Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Gr\u00e9goire MC, Coulon C, Valette H, Dolle F, Ribeiro MJ, Hantraye P, Remy P (2009) Decrease of nicotinic receptors in the nigrostriatal system in Parkinson\u2019s disease. J Cereb Blood Flow 29:1601\u20131608","journal-title":"J Cereb Blood Flow"},{"key":"1854_CR109","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.410320510","volume":"32","author":"DC German","year":"1992","unstructured":"German DC, Manaye KF, White CL III, Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32:667\u2013676","journal-title":"Ann Neurol"},{"key":"1854_CR110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337\u2013341","journal-title":"Arch Neurol"},{"key":"1854_CR111","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0306-4522(91)90345-O","volume":"41","author":"M Mavridis","year":"1991","unstructured":"Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson\u2019s disease. Neuroscience 41:507\u2013523","journal-title":"Neuroscience"},{"key":"1854_CR112","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2014.04.011","volume":"257","author":"E Shin","year":"2014","unstructured":"Shin E, Rogers JT, Devoto P, Bj\u00f6rklund A, Carta M (2014) Noradrenaline neuron degeneration contributes to motor impairments and development of l-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Exp Neurol 257:25\u201338","journal-title":"Exp Neurol"},{"key":"1854_CR113","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/syn.20535","volume":"62","author":"A Arai","year":"2008","unstructured":"Arai A, Tomiyama M, Kannari K, Kimura T, Suzuki C, Watanabe M, Kawarabayashi T, Shen H, Shoji M (2008) Reuptake of l-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson\u2019s disease via norepinephrine transporter. Synapse 62:632\u2013635","journal-title":"Synapse"},{"key":"1854_CR114","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","volume":"16","author":"B Gomez-Mancilla","year":"1993","unstructured":"Gomez-Mancilla B, B\u00e9dard PJ (1993) Effect of nondopaminergic drugs on l-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418\u2013427","journal-title":"Clin Neuropharmacol"},{"key":"1854_CR115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/syn.20709","volume":"64","author":"K Buck","year":"2010","unstructured":"Buck K, Ferger B (2010) The selective alpha1 adrenoceptor antagonist HEAT reduces l-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Synapse 64:117\u2013126","journal-title":"Synapse"},{"key":"1854_CR116","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1124\/jpet.111.179416","volume":"337","author":"D Lindenbach","year":"2011","unstructured":"Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C (2011) Behavioral and cellular modulation of l-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther 337:755\u2013765","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR117","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.46.6.1548","volume":"46","author":"AF Carpentier","year":"1996","unstructured":"Carpentier AF, Bonnet AM, Vidailhet M, Agid Y (1996) Improvement of levodopa-induced dyskinesia by propranolol in Parkinson\u2019s disease. Neurology 46:1548\u20131551","journal-title":"Neurology"},{"key":"1854_CR118","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1471-4159.2009.06482.x","volume":"112","author":"K Buck","year":"2010","unstructured":"Buck K, Voehringer P, Ferger B (2010) The alpha(2) adrenoceptor antagonist idazoxan alleviates l-DOPA induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 112:444\u2013452","journal-title":"J Neurochem"},{"key":"1854_CR119","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","volume":"16","author":"SH Fox","year":"2001","unstructured":"Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16:642\u2013650","journal-title":"Mov Disord"},{"key":"1854_CR120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","volume":"361","author":"R Grondin","year":"2000","unstructured":"Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361:181\u2013186","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1854_CR121","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","volume":"18","author":"JM Savola","year":"2003","unstructured":"Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 18:872\u2013883","journal-title":"Mov Disord"},{"key":"1854_CR122","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O Rascol","year":"2001","unstructured":"Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C (2001) Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16:708\u2013713","journal-title":"Mov Disord"},{"key":"1854_CR123","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1212\/WNL.0b013e31825f0451","volume":"79","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM (2012) Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79:163\u2013169","journal-title":"Neurology"},{"key":"1854_CR124","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1073\/pnas.89.17.8155","volume":"89","author":"D Levesque","year":"1992","unstructured":"Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155\u20138159","journal-title":"Proc Natl Acad Sci USA"},{"key":"1854_CR125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","volume":"347","author":"P Sokoloff","year":"1990","unstructured":"Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146\u2013151","journal-title":"Nature"},{"key":"1854_CR126","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1073\/pnas.94.7.3363","volume":"94","author":"R Bordet","year":"1997","unstructured":"Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioural sensitization to levodopa. Proc Natl Acad Sci USA 94:3363\u20133367","journal-title":"Proc Natl Acad Sci USA"},{"key":"1854_CR127","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm875","volume":"9","author":"E Bezard","year":"2003","unstructured":"Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762\u2013767","journal-title":"Nat Med"},{"key":"1854_CR128","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0306-4522(02)00548-1","volume":"116","author":"JM Kampen van","year":"2003","unstructured":"van Kampen JM, Stoessl AJ (2003) Effects of oligonucleotide antisense to dopamineD3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience 116:307\u2013314","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"1854_CR129","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.parkreldis.2004.11.005","volume":"11","author":"C Guigoni","year":"2005","unstructured":"Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, H\u00e5kansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E (2005) Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord 11(Suppl. 1):S25\u2013S29","journal-title":"Parkinsonism Relat Disord"},{"key":"1854_CR130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","volume":"35","author":"NP Visanji","year":"2009","unstructured":"Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM (2009) DopamineD3 receptor stimulation underlies the development of l-DOPA-induced dysk-inesia in animal models of Parkinson\u2019s disease. Neurobiol Dis 35:184\u2013192","journal-title":"Neurobiol Dis"},{"key":"1854_CR131","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbr.2014.01.011","volume":"263","author":"SR Cote","year":"2014","unstructured":"Cote SR, Chitravanshi VC, Bleickardt C, Sapru HN, Kuzhikandathil EV (2014) Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. Behav Brain Res 263:46\u201350","journal-title":"Behav Brain Res"},{"key":"1854_CR132","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.neuropharm.2009.01.020","volume":"56","author":"R Kumar","year":"2009","unstructured":"Kumar R, Riddle L, Griffin SA, Grundt P, Newman AH, Luedtke RR (2009) Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56:944\u2013955","journal-title":"Neuropharmacology"},{"key":"1854_CR133","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neuropharm.2009.01.019","volume":"56","author":"R Kumar","year":"2009","unstructured":"Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR (2009) Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology 56:956\u2013969","journal-title":"Neuropharmacology"},{"key":"1854_CR134","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.neuropharm.2009.08.017","volume":"58","author":"F Mela","year":"2010","unstructured":"Mela F, Millan MJ, Brocco M, Morari M (2010) The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect l-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. Neuropharmacology 58:528\u2013536","journal-title":"Neuropharmacology"},{"key":"1854_CR135","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/syn.20658","volume":"63","author":"EA Rabiner","year":"2009","unstructured":"Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle MA (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63:782\u2013793","journal-title":"Synapse"},{"key":"1854_CR136","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/brain\/awn337","volume":"132","author":"I Boileau","year":"2009","unstructured":"Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ (2009) Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson\u2019s disease. Brain 132:1366\u20131375","journal-title":"Brain"},{"key":"1854_CR137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnana.2011.00043","volume":"5","author":"A Nishi","year":"2011","unstructured":"Nishi A, Kuroiwa M, Shuto T (2011) Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons. Front Neuroanat 5:43","journal-title":"Front Neuroanat"},{"key":"1854_CR138","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd2058","volume":"5","author":"FS Menniti","year":"2006","unstructured":"Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660\u2013670","journal-title":"Nat Rev Drug Discov"},{"key":"1854_CR139","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","volume":"28","author":"A Nishi","year":"2008","unstructured":"Nishi A, Kuroiwa M, Miller DB, O\u2019Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, Snyder GL (2008) Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum. J Neurosci 28:10460\u201310471","journal-title":"J Neurosci"},{"key":"1854_CR140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0896-6273(00)80798-9","volume":"23","author":"P Greengard","year":"1999","unstructured":"Greengard P, Allen PB, Nairn AC (1999) Beyond the dopamine receptor: the DARPP-32\/protein phosphatase-1 cascade. Neuron 23:435\u2013447","journal-title":"Neuron"},{"key":"1854_CR141","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-7091-0932-8_18","volume":"970","author":"JA Girault","year":"2012","unstructured":"Girault JA (2012) Integrating neurotransmission in striatal medium spiny neurons. Adv Exp Med Biol 970:407\u2013429","journal-title":"Adv Exp Med Biol"},{"key":"1854_CR142","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0022-3565(25)39507-8","volume":"267","author":"MA Hossain","year":"1993","unstructured":"Hossain MA, Weiner N (1993) Dopaminergic functional supersensitivity: effects of chronic l-dopa and carbidopa treatment in an animal model of Parkinson\u2019s disease. J Pharmacol Exp Ther 267:1105\u20131111","journal-title":"J Pharmacol Exp Ther"},{"key":"1854_CR143","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1046\/j.1471-4159.1997.69051920.x","volume":"69","author":"CC Tenn","year":"1997","unstructured":"Tenn CC, Niles LP (1997) Sensitization of G protein-coupled benzodiazepine receptors in the striatum of 6-hydroxydopamine-lesioned rats. J Neurochem 69:1920\u20131926","journal-title":"J Neurochem"},{"key":"1854_CR144","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1460-9568.2008.06387.x","volume":"28","author":"M Giorgi","year":"2008","unstructured":"Giorgi M, D\u2019Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G (2008) Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci 28:941\u2013950","journal-title":"Eur J Neurosci"},{"key":"1854_CR145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","volume":"6","author":"B Picconi","year":"2003","unstructured":"Picconi B, Centonze D, H\u00e5kansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6:501\u2013506","journal-title":"Nat Neurosci"},{"key":"1854_CR146","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2007.10.001","volume":"29","author":"B Picconi","year":"2008","unstructured":"Picconi B, Paill\u00e9 V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela Cenci M, Calabresi P (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327\u2013335","journal-title":"Neurobiol Dis"},{"key":"1854_CR147","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/brain\/awq342","volume":"134","author":"B Picconi","year":"2011","unstructured":"Picconi B, Bagetta V, Ghiglieri V, Paill\u00e8 V, Di Filippo M, Pendolino V, Tozzi A, Giamp\u00e0 C, Fusco FR, Sgobio C, Calabresi P (2011) Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 134:375\u2013387","journal-title":"Brain"},{"key":"1854_CR148","first-page":"434","volume-title":"Dopamine Handbook","author":"MA Cenci","year":"2010","unstructured":"Cenci MA (2010) Pathophysiology of l-DOPA-induced dyskinesia in parkinson\u2019s disease. In: Dunnett S, Bj\u00f6rklund A, Iversen L, Iversen S (eds) Dopamine Handbook. Oxford University Press, New York, pp 434\u2013444"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-015-1854-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-015-1854-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-015-1854-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:55:11Z","timestamp":1747648511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-015-1854-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":148,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s00018-015-1854-x","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"type":"print","value":"1420-682X"},{"type":"electronic","value":"1420-9071"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}